Prof. Joseph M. Salvino is a Professor in the Molecular and Cellular Oncogenesis Program at Ellen and Ronald Caplan Cancer Center and a Scientific Director at the Molecular Screening & Protein Expression Facility. Prof. Joseph M. Salvino received his Ph.D. in organic chemistry from Brown University and completed his postdoctoral training in synthetic and medicinal chemistry at the University of Pennsylvania. Prof. Joseph M. Salvino is the first medicinal chemist to join Wistar’s staff, and his work to identify novel small-molecule lead compounds provides a strong basis for collaboration with all Wistar researchers. Prof. Joseph M. Salvino has more than 30 years of experience in drug discovery, including early-stage hit-to-lead, lead optimization, and preclinical development where several drug candidates have completed human clinical trials, including Entereg®, ADL-101, and Radezolid®. Before joining Wistar, Prof. Joseph M. Salvino was a professor in the Department of Pharmacology and Physiology at Drexel University College of Medicine. Before that, he held high-level positions including vice president, senior director, and director in the biotechnology and pharmaceutical industries of Sterling Winthrop, Rhone-Poulenc Rorer, Aventis, Rib-X Pharmaceuticals, Adolor Corporation, and Cephalon.